Herpetic Keratitis in Practice:
Diagnosis, Considerations, and Treatment Across Various Patient Types
Four experts in herpetic keratitis management gathered to discuss their perspectives
at the American Academy of Ophthalmology 2022 Annual Meeting in Chicago, IL.
Accessing ZIRGAN
See if your eligible patients are covered with Bausch + Lomb’s formulary tool.
Check our formulary toolIndication
ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
Important Safety Information
- ZIRGAN® is indicated for topical ophthalmic use only.
- Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN®.
- Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
- Safety and efficacy in pediatric patients below the age of 2 years have not been established.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.1-800-FDA-1088.
Click here for full Prescribing Information for ZIRGAN®.
ZIRGAN® is a trademark of Laboratoires Théa Corporation used under license.
References: 1. Foster CS. Ganciclovir gel—a new topical treatment for herpetic keratitis. US Ophthalmic Rev. 2007;3(1):52-56. 2. ZIRGAN [package insert]. Bridgewater, NJ: Bausch & Lomb Incorporated. 3. Croxtall JD. Ganciclovir ophthalmic gel 0.15%: in acute herpetic keratitis (dendritic ulcers). Drugs. 2011;71(5):603-610.
Indication
ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
Important Safety Information
- ZIRGAN® is indicated for topical ophthalmic use only.
- Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN®.
- Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
- Safety and efficacy in pediatric patients below the age of 2 years have not been established.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.1-800-FDA-1088.
Click here for full Prescribing Information for ZIRGAN®.
ZIRGAN® is a trademark of Laboratoires Théa Corporation used under license.
THIS WEBSITE IS INTENDED FOR U.S.
HEALTHCARE PROFESSIONALS ONLY.
Please choose an option below: